New hope for tough blood cancers: experimental drug JNJ-90189892 enters human testing

NCT ID NCT06651229

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90189892 alone, then testing it in combination with two other drugs (azacitidine and venetoclax) in both relapsed/refractory and newly diagnosed AML. The main goals are to check safety and find the right dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-90189892 (an experimental drug) given alone or with azacitidine and venetoclax
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat AML or MDS.
What could go wrong: This is an early Phase 1 trial, so the main goal is safety, not proof of effectiveness. Many experimental drugs fail at this stage, and side effects may be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE MYELODYSPLASTIC NEOPLASMS

Contacts and locations

Locations

CHRU de Strasbourg - Hopital de Hautepierre
RECRUITING

Strasbourg, 67200, France
Clinica Univ. de Navarra
RECRUITING

Pamplona, 31008, Spain
Concord Hospital
RECRUITING

Concord, 2139, Australia
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Virgen Rocio
RECRUITING

Seville, 41013, Spain
Institut Claudius Regaud
RECRUITING

Toulouse, 31100, France
Institut Paoli-Calmettes
RECRUITING

Marseille, 13273, France
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, 3000, Australia
Sir Charles Gairdner Hospital
RECRUITING

Nedlands, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.